TITLE

Should Treatment of Hepatitis C in HIV-Seropositive and HIV-Seronegative Patients with Hemophilia Include Induction Doses of Interferon?

AUTHOR(S)
McGovern, Barbara; Bica, Ioana
PUB. DATE
August 2003
SOURCE
Clinical Infectious Diseases;8/1/2003, Vol. 37 Issue 3, p463
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Presents a letter to the editor of the journal 'Clinical Infectious Diseases' about the inclusion of interferon in the treatment of hepatitis C in HIV-seropositive and -seronegative patients with hemophilia. First phase of viral decline in response to interferon therapy; Treatment of HIV-HCV-coinfected patients with more advanced liver disease.
ACCESSION #
10590286

 

Related Articles

  • Peginterferon-α-2a.  // Reactions Weekly;10/20/2012, Issue 1424, p40 

    The article describes a case of acquired haemophilia A in a woman that developed during treatment with peginterferon-α-2a for chronic viral hepatitis C.

  • Reply. Hanabusa, Hideji // Clinical Infectious Diseases;8/1/2003, Vol. 37 Issue 3, p464 

    Responds to comments about the author's article on the sustained viral response (SVR) of HIV-positive and -negative patients with hepatitis C virus (HCV) genotype 1 infections. Link between the degree of virus load reduction during the first phase of treatment and the second-phase decline...

  • Hepatitis C Cure After 6 Months of Telaprevir-Based Therapy in an HIV-Infected Man. Cachay, Edward R. // Clinical Infectious Diseases;Jan2013, Vol. 56 Issue 1, p163 

    The article discusses research conducted on hepatitis C cure after six months of telaprevir-based therapy in an HIV-infected man.

  • Intl Liver Congress 2012: Drug interactions won't exclude HCV transplant or HIV co-infected patients from treatment.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article provides information on a data presented at the International Liver Congress 2012 which found that drug interactions won't exclude hepatitis C transplant or HIV co-infected patients from treatment.

  • Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. Taylor, Lynn E.; Rich, Josiah D.; Tashima, Karen T. // New England Journal of Medicine;11/25/2004, Vol. 351 Issue 22, p2340 

    A letter to the editor is presented in response to an study entitled "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients," which was published in the July 29, 2004 issue.

  • Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. Gholam, Pierre M. // New England Journal of Medicine;11/25/2004, Vol. 351 Issue 22, p2340 

    A letter to the editor is presented in response to an study entitled "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients," which was published in the July 29, 2004 issue.

  • Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. Torriani, Francesca J.; Dieterich, Douglas T. // New England Journal of Medicine;11/25/2004, Vol. 351 Issue 22, p2340 

    A response by Francesca J. Torriani and Douglas T. Dietrich is presented to several letters to the editor in response to their study titled "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients," which was published in the July 29, 2004 issue.

  • Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. Chung, Raymond T.; Andersen, Janet; Volberding, Paul // New England Journal of Medicine;11/25/2004, Vol. 351 Issue 22, p2340 

    A response is presented by Raymond T. Chung, Janet Andersen, and Paul Volberding to a letter in response to their study titled "Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-infected patients," which was published in the July 29,...

  • Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C. Rakov, Neal E. // New England Journal of Medicine;1/16/2003, Vol. 348 Issue 3, p259 

    A letter to the editor is presented in response to the article "Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection," in the September 26, 2002 issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics